Cirmtuzumab

Drug Profile

Cirmtuzumab

Alternative Names: UC-961

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Oncternal Therapeutics, Inc.; University of California, San Diego
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia
  • Preclinical Breast cancer; Mantle-cell lymphoma; Ovarian cancer

Most Recent Events

  • 22 Feb 2017 Oncternal Therapeutics plans a phase Ib/II clinical trial in Lymphocytic leukaemia and Mantle cell lymphoma (Combination therapy)
  • 27 Jan 2017 Preclinical trials in Breast cancer in USA (Parenteral) before January 2017
  • 27 Jan 2017 Preclinical trials in Mantle cell lymphoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top